Molecular mechanisms to control therapeutic vulnerabilities of gastrointestinal cancers
Schneider Lab
The aim of the working group is to understand and decipher the molecular mechanisms within gastrointestinal cancers of the pancreas and rectum in order to make advances in personalized therapy. This interlinks patient care with clinical science ultimately leading to better patient care.
Research focus
The research focus of the working group are pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). Therin different projects aim to decipher the complex mechanisms leading to therapy resistance and disease progression. The downstream goal is improvement of patient care and survival through new personalized therapy options and drug combinations. The different projects reflect the complex nature of PDAC and CRC and target specific regulators or mechanisms of interest in disease progression.
Projects
- Epigenetic regulators e.g. HDACs, PRMTs as therapeutic targets
- Mutant KRAS-specific inhibitor combinations
- Drug-tolerant persisters
- Post-translational ubiquitin-like modifiers e.g. SUMO
- The role of Stress Granules in therapy resistance
- Large scale drug screenings
- Patient-derived cell culture models e.g. organoids
Lab-Members
Kontaktinformationen
- Telefon: +49 551 3920488
- E-Mail-Adresse: guenter.schneider(at)med.uni-goettingen.de
Alumni
Dr. Constanza Tapia Contreras, Postdoc
Rustgi Lab, Columbia University, Irving Medical Center
Dr. Engin Demirdizen, Postdoc
Funding
